Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts. Show more

180 Third Avenue, Waltham, MA, 02451, United States

Biotechnology

Healthcare

Market Cap

2.549B

52 Wk Range

$18.69 - $28.23

Previous Close

$19.67

Open

$19.83

Volume

723,141

Day Range

$18.50 - $20.31

Enterprise Value

2.04B

Cash

519.2M

Avg Qtr Burn

-68.31M

Insider Ownership

0.00%

Institutional Own.

42.83%

Qtr Updated

03/31/26

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
KAI-7535 (GLP-1 Agonist) Details Obesity	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ribupatide Oral (KAI-9531-T) (GLP-1/GIP Agonist) Details Obesity	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ribupatide Injection (KAI-9531) (GLP-1/GIP Agonist) Details Obesity Or Overweight	Phase 2b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.